

Published in final edited form as:

FEBS Lett. 2011 April 20; 585(8): 1223–1230. doi:10.1016/j.febslet.2011.03.042.

Diminished AMPK signaling response to fasting in Thioredoxin-interacting Protein Knockout Mice

Allen M. Andres^{*}, Eric P. Ratliff^{*}, Sowbarnika Sachithanatham^{*}, and Simon T. Hui^{*,†,‡}

^{*} Department of Biology, BioScience Center, San Diego State University, San Diego, CA 92182, USA

[†] Division of Cardiology, Department of Medicine, University of California, Los Angeles, CA 90095, USA

Abstract

Thioredoxin-interacting protein (Txnip) knockout (TKO) mice exhibit impaired response to fasting. Herein, we showed that activation of AMPK and cellular AMP levels were diminished in the heart and soleus muscle but not in gastrocnemius muscle of fasting TKO mice. Similarly, glycogen content in fasted TKO mice was increased in oxidative muscles but was not different in glycolytic muscles. These data suggest Txnip deficiency has a higher impact on oxidative muscle than glycolytic muscles and provide new insights into the metabolic role of Txnip.

Keywords

cellular AMP level; mitochondrial oxidation; glucose homeostasis; glycogen storage

1. INTRODUCTION

The ability to make proper adaptive biochemical and physiological changes in response to nutritional status is vital to the survival of all living organisms. Hence, the balance of metabolic fuel utilization is tightly regulated and coordinated. Disruption of this intricate balance is manifested in many common diseases in Western societies, such as obesity and diabetes. Previously, we and others showed that thioredoxin-interacting protein (Txnip) knockout (TKO) mice were unable to respond properly to energy deprivation [1–5]. Prolonged starvation resulted in the death of 90% TKO mice within 72 hours while acute fasting led to profound alternations in the plasma metabolic profile of TKO mice which become hypoglycemic, hyperketonemic and hypertriglyceridemic. Surprisingly, although the liver plays a central role in fuel adaptation, liver-specific Txnip knockout mice do not have any overt metabolic abnormalities [4]. On the other hand, cardiac and skeletal muscle-specific Txnip knockout mice recapitulate the fasting plasma metabolic profile of whole body TKO mice, indicating that the metabolic perturbations by Txnip ablation are mainly due to its loss of function in the heart and skeletal muscle. [4]. Mitochondrial oxidation of

© 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

[‡]Correspondence: Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1679, USA, sthui@mednet.ucla.edu, Tel: +1 (310) 825-2957, Fax: +1 (310) 794-7345.

The authors report that they have no conflicts of interest.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

glucose, fatty acids and ketone bodies in skeletal muscles was found to be reduced in TKO mice, whereas glucose uptake and glycolysis were increased [4].

Txnip is a 46 kDa ubiquitously expressed protein which is involved in maintaining cellular redox rheostat through its disulfide interaction with thioredoxin-1 [6,7]. It is an important metabolic regulator in controlling glucose homeostasis [1,4,5,8,9]. Elevated glucose levels induce Txnip expression [10–12]. Conversely, Txnip expression suppresses glucose uptake and utilization [8,13]. Txnip mutations are linked to lower plasma glucose in type 2 diabetic patients who have elevated levels of Txnip in the pancreatic β -cells [8,13].

AMP-activated protein kinase (AMPK) is the master energy sensor in the cell and orchestrates fasting-specific metabolic responses [review in [14]]. Activation of AMPK by increased cellular AMP levels inhibits anabolic pathways and promotes catabolic processes to restore ATP levels. Given the central role of AMPK in energy sensing and maintaining energy homeostasis, we investigated the possible link of Txnip ablation in skeletal and cardiac muscles to AMPK signaling and glucose homeostasis.

2. MATERIALS AND METHODS

2.1 Animal Studies

Generation of Txnip knockout mice was described previously [4]. All studies were performed on overnight fasted mice except where otherwise stated. All procedures described were approved by the Institutional Animal Care and Use Committee at San Diego State University and University of California at Los Angeles.

2.2 Isolation of Total RNA and Quantitative Real-Time PCR

Total RNA was isolated from frozen tissue samples using the PerfectPure RNA Isolation Kit (5-Prime). cDNA was generated using iScript cDNA Synthesis Kit (BioRad). Quantitative real-time PCR was performed using the SensiMix Plus SYBR Green Kit (Quantace) on the iCycler system (BioRad). Primers used for GLUT1 mRNA expression were 5'-GGTGTGCAGCAGCCTGTGTA-3' (forward) and 5'-AACAAACAGCGACACCACAGT-3' (reverse). GLUT1 expression levels were normalized to that of cyclophilin. Primer sequences for cyclophilin were 5'-TGGAGAGCACCAAGACAGACA-3' (forward) and 5'-TGCCGGAGTCGACAATGAT-3' (reverse).

2.3 Western Blotting

Tissues were homogenized in ice-cold buffer containing 50 mM Tris pH 8, 150 mM NaCl, 2 mM EGTA, 1 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 20 mM NaF, 1 mM NaVO₄, 1 mM PMSF, 10 μ g/ml aprotinin, 10 μ g/ml leupeptin and 10 μ g/ml pepstatin. Anti-tubulin antibody was purchased from Sigma. Anti-pPDH-E1 α (Ser-293) was purchased from Calbiochem. Antibodies for LKB1, GLUT1 and GLUT4 were purchased from Santa Cruz Biotechnology. All other primary antibodies were purchased from Cell Signaling Technology.

2.4 AICAR Treatment

Overnight fasted mice were given a subcutaneous injection of 5-Aminoimidazole-4-carboxamide ribonucleoside (AICAR, 0.5 mg/g body weight). Control animals received saline only. One hour after injection, mice were sacrificed and soleus muscles were processed for Western blot analysis.

2.5 AMPK activity Assay

Tissue were homogenized in Buffer A (50 mM Tris-HCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 50 mM NaF, 5 mM sodium pyrophosphate, 10% glycerol, 1% TritonX-100, pH 7.50) in the presence of protease inhibitor cocktail (Pierce). The homogenate was centrifuged for 15 min at $13,500 \times g$. AMPK activity was determined using SAMS peptide as a substrate in the presence of 200 μ M AMP as described [15]. The standard assay mixture (in 25 μ l) contains 40 mM HEPES (pH 7.0), 80 mM NaCl, 8% glycerol (v/v), 5 mM MgCl₂, 0.8 mM EDTA, 0.8 mM dithiothreitol, 0.2 mM ATP, 0.2 mM AMP, 0.2 mM SAMS peptide and 2 μ Ci [³²P]ATP (cat# 35001X, ICN). After 20 min at 30°C, the reaction was terminated by spotting 15 μ l of reaction mixture onto Whatman P81 paper, which was then washed 5 times in 1% phosphoric acid and once in acetone. The papers were air-dried and radioactivity was quantitated in 4 ml scintillation fluid. Activities of each sample were corrected from no-enzyme controls and normalized to the amount of protein.

2.6 Quantification of Tissue Nucleotides

Assay of nucleotides levels were performed by the NIH Mouse Metabolic Phenotyping Center at the Yale University School of Medicine. Tissues were snap-frozen in liquid nitrogen. Frozen tissues (50 to 100 mg) were extracted with 0.9 N ice-cold perchloric acid. The concentrations of ATP, ADP, and AMP in the supernatant were determined by LC/MS.

2.7 Tissue Glycogen Content

Frozen tissues (20–50 mg) were dissolved in 1 N KOH for 20 min at 65 °C and treated with activated amyloglucosidase (Sigma) in an acidic buffer overnight at room temperature. Samples were then neutralized with 1 N NaOH and assayed using a glucose kit (Wako). Tissue glycogen content is expressed as the amount free glycosyl units (μ mol)/g tissue.

2.8 Subcellular Fractionation

For LKB1 measurements, cytosolic and nuclear fractions were prepared as described [16]. For GLUT4 analysis, tissues from overnight fasted mice were subfractionated as described [17] with minor modifications. The final pellet was resuspended in buffer containing 30% sucrose and subject to centrifugation ($216,000 \times g$) for 1 hr at 4 °C to separate the intracellular membranes from the plasma membranes. GLUT4 protein levels were determined in the membrane fractions by Western blotting.

2.9 Measurement of Plasma insulin

Plasma insulin levels of fasted and non-fasted animals were determined by the Mouse Insulin Lincoplex kit from Millipore.

2.10 Measurement of 2-Deoxyglucose uptake

Deoxyglucose uptake in soleus from overnight fasted mice was determined as described [18]. Soleus muscle from overnight fasted mice was pre-incubated in oxygenated Krebs-Henseleit Buffer (KHB) without insulin for 30 min. Muscles were then incubated for 20 min. in KHB containing 1 mM 2-deoxy-D-[1,2-³H]glucose (2.25 μ Ci/ml), 0.3 μ Ci/ml [U-¹⁴C]mannitol, 2 mM sodium pyruvate and 0.1% BSA. Tissue was blotted dry and digested in Tissue Solubilizer (ICN). Radioactivity was determined by scintillation counting in the presence of 10 ml Cytoscint (Fisher). The amount of each isotope present in the samples was determined and this information was used to calculate the extracellular space and the intracellular concentration of 2-deoxyglucose. Rates of uptake were normalized to wet muscle mass in each vial.

2.11 Statistical Methods

All data are reported as the mean \pm standard deviation. Group mean values were compared by Student's two-tailed t-test. Results with p-values < 0.05 were considered statistically significant.

3. RESULTS

3.1 Activation of AMPK is reduced in oxidative muscle tissues of fasting TKO mice

We previously demonstrated that cardiac and skeletal muscle-specific Txnip KO mice recapitulated the metabolic phenotype of whole body Txnip KO mice [4]. Since AMPK is the major energy sensor orchestrating adaptive metabolic changes to fasting, we investigated if Txnip ablation would affect AMPK signaling in the heart and skeletal muscle. While total AMPK α protein level in TKO mice was the same as wild-type (WT) mice, activation of AMPK α through Thr-172 phosphorylation was markedly diminished in soleus and hearts of fasted TKO mice (Fig. 1A). In contrast, there was no difference in AMPK activation in soleus and hearts of non-fasted TKO mice, as compared to the WT controls (Fig. 1B). Interestingly, activation of AMPK was also not diminished in gastrocnemius from both fasted and non-fasted TKO mice (Fig. 1A & B). These findings suggest that Txnip ablation exerts different effects on oxidative muscles (soleus and cardiac muscle) than glycolytic muscles (gastrocnemius). Consistent with reduced AMPK activation, phosphorylation of acetyl-CoA carboxylase (ACC) at Ser-79, a downstream AMPK phosphorylation target, was also diminished in the fasting heart and soleus but not in gastrocnemius (Fig. 1C). The reduction in AMPK activation in fasting soleus and hearts was further confirmed by the decrease in AMPK activity measured in vitro (Fig. 1D).

3.2 Activation of AMPK by LKB1 and AMP are normal in TKO mice

Txnip knockout mice exhibit increased insulin sensitivity [4,19,20]. Phosphorylation of AMPK at Ser-485/491 (AMPK α) by the serine/threonine protein kinase B (Akt) is known to inhibit Thr-172 phosphorylation [21]. We examined if the decrease in AMPK activation could be due to cross-talk inhibition exerted by the insulin/Akt pathway through Ser-485/491 phosphorylation of AMPK α . No difference in Ser-485/491 phosphorylation levels between TKO mice and WT control mice was observed (Fig. 2). These data suggest that hypo-phosphorylation of AMPK at Thr-172 is unlikely due to the inhibitory action by Akt.

Since liver kinase B1 (LKB1) is the major upstream kinase that phosphorylates AMPK in response to energy deprivation [22], we examined whether ablation of Txnip may have affected the function of LKB1. TKO mice have similar expression levels of LKB1 as that of WT mice (Fig. 3A), indicating that Txnip ablation did not alter LKB1 protein expression. Nucleocytoplasmic transport and subsequent association of LKB1 with STE20-related adaptor protein (STRAD) and the scaffolding protein calcium binding protein 39 (CAB39) in the cytoplasm are required for full activation of LKB1 and AMPK [23]. Fig. 3A showed that cytosolic and nuclear distribution of LKB1 level was not altered in TKO mice. To confirm that LKB1 enzyme activity is not deficient in TKO mice, we examined the phosphorylation status of MAP/microtubule affinity-regulating kinase 1 (MARK1), another established LKB1 phosphorylation target. Fig. 3B showed that levels of MARK1 phosphorylation in TKO mice were the same as that of WT controls. Taken together, these findings showed that diminished activation of AMPK in fasting TKO mice is not due to LKB1 deficiency. We next examined if sensing of AMP by AMPK is defective in TKO mice. WT and TKO mice were treated with AICAR, an AMP analog which is metabolized to AICAR monophosphate (ZMP) mimicking the stimulatory effects of AMP on AMPK [24]. As expected, WT mice treated with AICAR exhibited a robust increase in Thr-172

phosphorylation of AMPK when compared to the saline-injected controls (Fig. 4). Interestingly, TKO mice were equally responsive to AICAR treatment (Fig. 4), suggesting that the mechanism by which AMP activates AMPK is intact in TKO mice.

3.3 Txnip ablation alters cellular AMP:ATP ratio

Results from the AICAR stimulation experiment strongly suggest that intracellular AMP levels may explain the difference in AMPK activation. Levels of cellular adenosine nucleotides in tissues from fasted WT and TKO mice were quantified by LC/MS (Table 1). In both soleus and hearts, AMP levels in TKO mice were significantly reduced compared to WT mice (70.7% and 32.0%, $p=0.002$ and 0.006 respectively). Consistent with the finding that AMPK phosphorylation was not affected in gastrocnemius, AMP level in gastrocnemius from fasted TKO mice was not different from that of WT controls. Fasting ATP level in soleus and gastrocnemius of TKO mice were both elevated (14.4%, $p=0.037$ and 21.8%, $p=0.0001$ respectively) whereas it was reduced in the heart (9.7%, $p=0.001$). AMP:ATP ratio was lower in all three tissues of TKO mice: soleus (74.5%, $p=0.002$), hearts (24.6%, $p=0.034$) and gastrocnemius (20.8%, $p=0.005$). Taken together, these data showed that diminished AMPK activation in fasting TKO soleus and hearts is not due to deficiencies in upstream kinase function or the capability of AMP to stimulate AMPK, but rather a consequence of decreased cellular AMP levels.

3.4 Increased glucose utilization in muscle tissues of TKO mice is not associated with glucose transporter expression

One of the key functions of AMPK is to increase glucose uptake and utilization in response to energy deprivation. Paradoxically, we found that both glucose uptake and glycolysis were elevated in fasting TKO mice [4] despite having blunted AMPK activation (Fig. 1). Plasma levels of insulin in fasting TKO mice are the same as that of WT mice, whereas insulin levels of non-fasting TKO mice are lower than that of WT mice (Fig. 5A). Soleus isolated from fasting TKO mice showed increased 2-deoxyglucose uptake in the absence of insulin (Fig. 5B). This finding is consistent with those of Patwari et al. who showed that overexpression of Txnip in cultured 3T3-L1 adipocytes reduced 2-deoxyglucose uptake in the absence of insulin [13].

We examined if Txnip ablation alters the expression of glucose transporters GLUT4 and GLUT1. Heart tissues from WT and TKO mice were subfractionated. Purity and enrichment of plasma membrane was assessed by the presence of the cell surface marker β 1-integrin (Fig. 6A, top panel). Induction of GLUT4 expression in plasma membrane samples from AICAR-stimulated WT mice served as positive controls (Fig. 6A, top panel). No difference was observed in the abundance of GLUT4 protein on the plasma membrane between TKO and WT mice (Fig. 6A, bottom panel). Unexpectedly, GLUT1 protein levels in the heart, soleus and gastrocnemius were lower in fasted TKO mice (Fig. 6B); however, no difference was observed in non-fasted animals (Fig. 6C). Parallel to the fasting GLUT1 protein difference, GLUT1 mRNA expression was diminished in fasted TKO mice, suggesting that the reduction in GLUT1 protein levels is due to transcriptional down-regulation (Fig. 6D). Since GLUT1 mRNA levels were reduced in gastrocnemius despite the absence of impairment in AMPK activation, these findings indicate the down-regulation of GLUT1 expression by Txnip ablation acts through a mechanism independent to AMPK signaling.

3.5 Txnip ablation induces inhibition of the mitochondrial pyruvate dehydrogenase complex, and is associated with increased muscle glycogen content

High energy state (low AMP:ATP ratio) activates pyruvate dehydrogenase kinases (PDKs) [25] which in turn phosphorylates and inhibits pyruvate dehydrogenase (PDH) [26].

Phosphorylation levels of the PDH-E1 α subunit was markedly increased in soleus muscle from fasting TKO mice (Fig. 7A) whereas no difference was observed in non-fasted mice ($p=0.07$, Fig. 7B). This finding is consistent with our previous data showing that glucose oxidation was diminished whereas lactate production and glycolysis were increased in fasted TKO soleus muscles [4].

Glycogen content in the heart and soleus of fasted TKO mice were dramatically increased (5.6-fold and 5.3-fold respectively, Fig. 8A). In non-fasted animals, a trend towards increased glycogen content in the hearts and soleus of TKO mice versus WT controls was observed, but did not reach statistical significance ($p=0.21$ and 0.06 respectively, Fig. 8B). In contrast, glycogen content in the gastrocnemius of fasted and non-fasted TKO mice were not increased comparing to WT controls (Fig. 8A & B).

4. DISCUSSION

Negative feedback mechanisms provide fail-safe measures to regain homeostasis in biological systems. In the case of counteracting energy deprivation (as in fasting and impaired mitochondrial oxidation), AMPK senses the decline in cellular energy status and coordinately modifies metabolic pathways to increase ATP production [14]. Activation of mitochondrial fatty acid oxidation by AMPK signaling in skeletal muscle provides a means to spare glucose for the brain, which relies on glucose as the major source of energy during acute fasting [27]. We previously showed that mitochondrial oxidation of glucose, fatty acids and ketone bodies were reduced in fasted TKO mice [4]. In this study, we further characterized the metabolic consequences of Txnip ablation and show for the first time that AMPK activation is blunted in the heart and soleus muscle, but not gastrocnemius muscle, of fasted TKO mice (Fig. 1A). The reduction in AMPK activation is associated with a decrease in cellular levels of AMP. This change is specific to tissues enriched in oxidative fibers (heart and soleus muscle) but not in those high in glycolytic fibers (gastrocnemius) (Table 1). The fact that gastrocnemius muscle has a high capacity of glycolysis may explain why it is less susceptible to the effect of impaired mitochondrial oxidation and increased glucose uptake caused by Txnip deficiency. In contrary, cardiac and soleus muscles contain more oxidative fibers and thus are more reliant on mitochondrial oxidation. As a result, the surplus glucose influx is channeled into glycogen storage. This is supported by our finding that glycogen accumulates in heart and soleus of fasting TKO mice but not in gastrocnemius (Fig. 8).

Despite having impaired mitochondrial fuel oxidation, we made a surprising finding that tissues of fasted TKO mice were in a paradoxically higher energetic state (Table 1). As glucose oxidation is impaired in TKO mice, The paradoxical finding of an elevated energy state in fasted TKO mice could be attributed, at least in part, to the increase in glycolysis as previously reported [4]. Reduced AMP:ATP ratio favors the phosphorylation and inhibition of PDH through the activation of PDKs. Forced expression of PDK1 in hypoxic HIF-1 α null cells has been shown to increase ATP levels and shunt glucose metabolites from the mitochondria to glycolysis [28].

It is presently unclear how Txnip ablation leads to increased glucose uptake. Fasting insulin levels of TKO mice were not different from WT mice (Fig. 5A). Although fasted TKO mice have been shown to have increased insulin sensitivity [4,20], we did not observe any increase in GLUT4 translocation to the plasma membrane in TKO hearts (Fig. 6A). This may be attributed to the reduced AMPK signaling in TKO hearts which leads to decreased phosphorylation of Akt substrate of 160kDa (AS160) and GLUT4 translocation [29]. Uptake of 2-deoxyglucose in the absence of insulin by isolated soleus from fasting TKO mice was increased comparing to WT controls (Fig. 5B). In accordance with findings from

overexpression studies of Txnip in cultured adipocytes [13], our data suggest that increased uptake of glucose in muscle is likely mediated by an insulin-independent mechanism. Previously, we showed that streptozotocin treatment normalized plasma triglyceride levels in Txnip null HcB-19 mice and led to hyperglycemia in both control and HcB-19 mice. The seemingly contradicting findings on the role of insulin in these two studies can be reconciled by the fact that insulin affects glucose secretion by the liver but not glucose uptake in the muscle. Absence of insulin in streptozotocin-treated mice suppresses hepatic lipoprotein and leads to uncontrolled hepatic glucose output.

Despite have increased glucose uptake, GLUT1 protein expression was unexpectedly lower in fasting TKO mice whereas no difference was observed in non-fasting animals (Fig. 6B & C). The down-regulation of GLUT1 transcription appears to be independent to AMPK as GLUT1 expression in gastrocnemius from fasting TKO mice was also reduced (Fig. 6D). The role of Txnip in regulating GLUT1 remains to be elucidated. However, our data indicate that modulation of glucose uptake by Txnip does not involve increased recruitment of the two most abundant glucose transporters, namely GLUT1 and GLUT4, in the muscle. Mutagenesis studies demonstrated that modulation of glucose uptake by Txnip in cultured cells was independent of its ability to bind thioredoxin-1 and that regulation of glucose uptake was intrinsic to the arrestin-like domain in Txnip [13]. This raised the possibility that Txnip might act as a scaffold protein facilitating the interactions between other regulatory proteins of glucose metabolism. For example, it was discovered that Txnip interacts with NLRP3 and plays an essential role in regulating inflammasome activities [30]. Interestingly, NLRP3 knockout mice also exhibited increased glucose tolerance and insulin sensitivity similar to the phenotype of TKO mice, suggesting that the inflammasome pathway could be linked to the regulation of glucose homeostasis by Txnip [30]. Although the present study cannot exclude the possibility of alterations in other hexose transporters and their kinetic properties, a plausible explanation for the increase in glucose uptake without apparent increase in GLUT1 and GLUT4 expression could be, in part, due to increased rate of glycolysis [4] and the diversion of glucose metabolites to glycogen storage (Fig. 8).

McBride et al. demonstrated that glycogen inhibited AMPK activity in a highly purified cell-free system [31]. AMPK associates with glycogen synthase and glycogen phosphorylase in skeletal muscle [32]. The β subunits of AMPK contain a central conserved glycogen-binding domain which mediates the association between AMPK and glycogen. These findings suggest that AMPK may monitor the level of cellular energy reserve in the form of glycogen, in addition to its well-established role as immediate energy sensor of the AMP:ATP ratio. Physiological studies also showed that muscle AMPK activity is modulated by glycogen content [33,34]; however, the underlying mechanisms are poorly understood. Glycogen depleted muscle exhibits greater AMPK activation by AICAR treatment or by exercise, whereas glycogen loading represses AMPK activation [33,34]. In fasted TKO mice, cellular glycogen content was found to be dramatically increased in soleus and hearts (Fig. 8). This is in line with data from hyperinsulinemic-euglycemic clamp studies showing that whole body rates of glycolytic and glycogen synthesis were significantly elevated in TKO mice [35]. The increased glycogen content, in addition to the observed decrease in AMP levels, may further attenuate AMPK activation. Similar to the metabolic phenotype of TKO mice, increased plasma lactate levels and muscle glycogen content are associated with human mitochondrial insufficiency disorders [36–38].

Txnip is intimately linked to cellular carbohydrate and mitochondrial metabolism through the glucose sensing transcriptional complex MondoA:MiX [39–41]. Increased glycolytic flux down-regulates Txnip gene expression [41]. Induction of Txnip by lactic acidosis acts as a feedback mechanism to reduce glucose uptake and lactate production whereas this protective measure is blunted in Txnip deficient cells [40]. In addition to promoting mitochondrial

oxidation to generate ATP from fatty acid and ketone bodies oxidation, AMPK reduces the deleterious effects of lactic acidosis. Activation of AMPK in skeletal muscle induces the expression of monocarboxylate transporter-4 [42], which is the predominant transporter for lactate efflux. The inability of TKO mice to up-regulate Txnip and activate AMPK pathway could reduce the tolerance to lactic acidosis and contribute to the increased mortality during long term fasting. Glucose sparing by skeletal muscles during fasting is a crucial evolutionary adaptation to survival since the brain can only utilize glucose as energy source during early stage of starvation. Our studies highlight the indispensable role of Txnip in maintaining glucose homeostasis and adapting to starvation through AMPK signaling.

Acknowledgments

We are grateful to the late Roger Davis for his inspiration and encouragement. We thank Jake Lusis and Alan Attie for their helpful insights and comments on the manuscript. This study was supported by grants to S.T.H from the National Institute of Health (DK080339) and American Heart Association Beginning Grant-in-aid (0665535Y). A.M.A. and E.P.R. were partly supported by scholarships from the ARCS Foundation and the Rees-Stealy Research Foundation.

ABBREVIATIONS

Txnip	thioredoxin-interacting protein
TKO	Txnip knockout
AMPK	adenine monophosphate-activated protein kinase
ACC	acetyl-CoA carboxylase
LKB1	liver kinase B1
STRAD	STE20-related adaptor protein
CAB39	calcium binding protein 39
MARK1	MAP/microtubule affinity-regulating kinase 1
AICAR	5-Aminoimidazole-4-carboxamide ribonucleoside
PDKs	pyruvate dehydrogenase kinases
ZMP	AICAR monophosphate
PDKs	pyruvate dehydrogenase kinases
PDH	pyruvate dehydrogenase
AS160	Akt substrate of 160kDa


References

1. Bodnar JS, Chatterjee A, Castellani LW, Ross DA, Ohmen J, Cavalcoli J, Wu C, Dains KM, Catanese J, Chu M, Sheth SS, Charugundla K, Demant P, West DB, de Jong P, Lusis AJ. Positional cloning of the combined hyperlipidemia gene Hyplip1. *Nat Genet.* 2002; 30:110–116. [PubMed: 11753387]
2. Chutkow WA, Patwari P, Yoshioka J, Lee RT. Thioredoxin-interacting protein (Txnip) is a critical regulator of hepatic glucose production. *J Biol Chem.* 2008; 283:2397–2406. [PubMed: 17998203]
3. Oka S, Liu W, Masutani H, Hirata H, Shinkai Y, Yamada S, Yoshida T, Nakamura H, Yodoi J. Impaired fatty acid utilization in thioredoxin binding protein-2 (TBP-2)-deficient mice: a unique animal model of Reye syndrome. *Faseb J.* 2006; 20:121–123. [PubMed: 16254043]
4. Hui ST, Andres AM, Miller AK, Spann NJ, Potter DW, Post NM, Chen AZ, Sachithanatham S, Jung DY, Kim JK, Davis RA. Txnip balances metabolic and growth signaling via PTEN disulfide reduction. *Proc Natl Acad Sci U S A.* 2008; 105:3921–3926. [PubMed: 18322014]

5. Hui TY, Sheth SS, Diffley JM, Potter DW, Lusic AJ, Attie AD, Davis RA. Mice lacking thioredoxin-interacting protein provide evidence linking cellular redox state to appropriate response to nutritional signals. *J Biol Chem.* 2004; 279:24387–24393. [PubMed: 15047687]
6. Nishiyama A, Matsui M, Iwata S, Hirota K, Masutani H, Nakamura H, Takagi Y, Sono H, Gon Y, Yodoi J. Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. *J Biol Chem.* 1999; 274:21645–21650. [PubMed: 10419473]
7. Patwari P, Higgins LJ, Chutkow WA, Yoshioka J, Lee RT. The interaction of thioredoxin with Txnip. Evidence for formation of a mixed disulfide by disulfide exchange. *J Biol Chem.* 2006; 281:21884–21891. [PubMed: 16766796]
8. Parikh H, Carlsson E, Chutkow WA, Johansson LE, Storgaard H, Poulsen P, Saxena R, Ladd C, Schulze PC, Mazzini MJ, Jensen CB, Krook A, Bjornholm M, Tornqvist H, Zierath JR, Ridderstrale M, Altshuler D, Lee RT, Vaag A, Groop LC, Mootha VK. TXNIP regulates peripheral glucose metabolism in humans. *PLoS Med.* 2007; 4:e158. [PubMed: 17472435]
9. Sheth SS, Castellani LW, Chari S, Wagg C, Thippavong CK, Bodnar JS, Tontonoz P, Attie AD, Lopaschuk GD, Lusic AJ. Thioredoxin-interacting protein deficiency disrupts the fasting-feeding metabolic transition. *J Lipid Res.* 2005; 46:123–134. [PubMed: 15520447]
10. Hirota T, Okano T, Kokame K, Shirohara-Ikejima H, Miyata T, Fukada Y. Glucose down-regulates Per1 and Per2 mRNA levels and induces circadian gene expression in cultured Rat-1 fibroblasts. *J Biol Chem.* 2002; 277:44244–44251. [PubMed: 12213820]
11. Shalev A, Pise-Masison CA, Radonovich M, Hoffmann SC, Hirshberg B, Brady JN, Harlan DM. Oligonucleotide microarray analysis of intact human pancreatic islets: identification of glucose-responsive genes and a highly regulated TGFbeta signaling pathway. *Endocrinology.* 2002; 143:3695–3698. [PubMed: 12193586]
12. Pang ST, Hsieh WC, Chuang CK, Chao CH, Weng WH, Juang HH. Thioredoxin-interacting protein: an oxidative stress-related gene is upregulated by glucose in human prostate carcinoma cells. *J Mol Endocrinol.* 2009; 42:205–214. [PubMed: 19052253]
13. Patwari P, Chutkow WA, Cummings K, Verstraeten VL, Lammerding J, Schreiter ER, Lee RT. Thioredoxin-independent regulation of metabolism by the alpha-arrestin proteins. *J Biol Chem.* 2009; 284:24996–25003. [PubMed: 19605364]
14. Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. *Circ Res.* 2007; 100:328–341. [PubMed: 17307971]
15. Derave W, Ai H, Ihlemann J, Witters LA, Kristiansen S, Richter EA, Ploug T. Dissociation of AMP-activated protein kinase activation and glucose transport in contracting slow-twitch muscle. *Diabetes.* 2000; 49:1281–7. [PubMed: 10923626]
16. Vitorino R, Ferreira R, Neuparth M, Guedes S, Williams J, Tomer KB, Domingues PM, Appell HJ, Duarte JA, Amado FM. Subcellular proteomics of mice gastrocnemius and soleus muscles. *Anal Biochem.* 2007; 366:156–169. [PubMed: 17540331]
17. Zhou M, Sevilla L, Vallega G, Chen P, Palacin M, Zorzano A, Pilch PF, Kandror KV. Insulin-dependent protein trafficking in skeletal muscle cells. *Am J Physiol.* 1998; 275:E187–196. [PubMed: 9688618]
18. Hansen PA, Gulve EA, Holloszy JO. Suitability of 2-deoxyglucose for in vitro measurement of glucose transport activity in skeletal muscle. *J Appl Physiol.* 1994; 76:979–85. [PubMed: 8175614]
19. Oka S, Masutani H, Liu W, Horita H, Wang D, Kizaka-Kondoh S, Yodoi J. Thioredoxin-binding protein-2-like inducible membrane protein is a novel vitamin D3 and peroxisome proliferator-activated receptor (PPAR)gamma ligand target protein that regulates PPARgamma signaling. *Endocrinology.* 2006; 147:733–743. [PubMed: 16269462]
20. Yoshihara E, Fujimoto S, Inagaki N, Okawa K, Masaki S, Yodoi J, Masutani H. Disruption of TBP-2 ameliorates insulin sensitivity and secretion without affecting obesity. *Nat Commun.* 2010; 1:127. [PubMed: 21119640]
21. Soltys CL, Kovacic S, Dyck JR. Activation of cardiac AMP-activated protein kinase by LKB1 expression or chemical hypoxia is blunted by increased Akt activity. *Am J Physiol Heart Circ Physiol.* 2006; 290:H2472–2479. [PubMed: 16428351]

22. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, Cantley LC. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. *Proc Natl Acad Sci U S A*. 2004; 101:3329–3335. [PubMed: 14985505]
23. Xie Z, Dong Y, Zhang J, Scholz R, Neumann D, Zou MH. Identification of the serine 307 of LKB1 as a novel phosphorylation site essential for its nucleocytoplasmic transport and endothelial cell angiogenesis. *Mol Cell Biol*. 2009; 29:3582–3596. [PubMed: 19414597]
24. Hardie DG, Carling D, Carlson M. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? *Annu Rev Biochem*. 1998; 67:821–855. [PubMed: 9759505]
25. Harris RA, Bowker-Kinley MM, Huang B, Wu P. Regulation of the activity of the pyruvate dehydrogenase complex. *Adv Enzyme Regul*. 2002; 42:249–259. [PubMed: 12123719]
26. Hue L, Taegtmeier H. The Randle Cycle Revisited: A New Head for an Old Hat. *Am J Physiol Endocrinol Metab*. 2009
27. Koh HJ, Brandauer J, Goodyear LJ. LKB1 and AMPK and the regulation of skeletal muscle metabolism. *Curr Opin Clin Nutr Metab Care*. 2008; 11:227–232. [PubMed: 18403917]
28. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. *Cell Metab*. 2006; 3:177–185. [PubMed: 16517405]
29. Yuasa T, et al. The Rab GTPase-activating protein AS160 as a common regulator of insulin- and Galphaq-mediated intracellular GLUT4 vesicle distribution. *Endocr J*. 2009; 56:345–59. [PubMed: 19139597]
30. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. *Nat Immunol*. 2010; 11:136–140. [PubMed: 20023662]
31. McBride A, Ghilagaber S, Nikolaev A, Hardie DG. The glycogen-binding domain on the AMPK beta subunit allows the kinase to act as a glycogen sensor. *Cell Metab*. 2009; 9:23–34. [PubMed: 19117544]
32. Chen Z, Heierhorst J, Mann RJ, Mitchelhill KI, Michell BJ, Witters LA, Lynch GS, Kemp BE, Stapleton D. Expression of the AMP-activated protein kinase beta1 and beta2 subunits in skeletal muscle. *FEBS Lett*. 1999; 460:343–348. [PubMed: 10544261]
33. Wojtaszewski JF, MacDonald C, Nielsen JN, Hellsten Y, Hardie DG, Kemp BE, Kiens B, Richter EA. Regulation of 5'AMP-activated protein kinase activity and substrate utilization in exercising human skeletal muscle. *Am J Physiol Endocrinol Metab*. 2003; 284:E813–822. [PubMed: 12488245]
34. Wojtaszewski JF, Jorgensen SB, Hellsten Y, Hardie DG, Richter EA. Glycogen-dependent effects of 5-aminoimidazole-4-carboxamide (AICA)-riboside on AMP-activated protein kinase and glycogen synthase activities in rat skeletal muscle. *Diabetes*. 2002; 51:284–292. [PubMed: 11812734]
35. Chutkow WA, Birkenfeld AL, Brown JD, Lee HY, Frederick DW, Yoshioka J, Patwari P, Kursawe R, Cushman SW, Plutzky J, Shulman GI, Samuel VT, Lee RT. Deletion of the {alpha}-Arrestin Protein Txnip in Mice Promotes Adiposity and Adipogenesis While Preserving Insulin Sensitivity. *Diabetes*. 2010; 59:1424–1434. [PubMed: 20299477]
36. Horvath R, Kemp JP, Tuppen HA, Hudson G, Oldfors A, Marie SK, Moslemi AR, Servidei S, Holme E, Shanske S, Kollberg G, Jayakar P, Pyle A, Marks HM, Holinski-Feder E, Scavina M, Walter MC, Coku J, Gunther-Scholz A, Smith PM, McFarland R, Chrzanowska-Lightowlers ZM, Lightowlers RN, Hirano M, Lochmuller H, Taylor RW, Chinnery PF, Tulinius M, DiMauro S. Molecular basis of infantile reversible cytochrome c oxidase deficiency myopathy. *Brain*. 2009; 132:3165–3174. [PubMed: 19720722]
37. Roodhooft AM, Van Acker KJ, Martin JJ, Ceuterick C, Scholte HR, Luyt-Houwen IE. Benign mitochondrial myopathy with deficiency of NADH-CoQ reductase and cytochrome c oxidase. *Neuropediatrics*. 1986; 17:221–226. [PubMed: 3027606]
38. Valente L, Tiranti V, Marsano RM, Malfatti E, Fernandez-Vizarra E, Donnini C, Mereghetti P, De Gioia L, Burlina A, Castellani C, Comi GP, Savasta S, Ferrero I, Zeviani M. Infantile encephalopathy and defective mitochondrial DNA translation in patients with mutations of mitochondrial elongation factors EFG1 and EFTu. *Am J Hum Genet*. 2007; 80:44–58. [PubMed: 17160893]

39. Stoltzman CA, Peterson CW, Breen KT, Muoio DM, Billin AN, Ayer DE. Glucose sensing by MondoA:MLx complexes: a role for hexokinases and direct regulation of thioredoxin-interacting protein expression. *Proc Natl Acad Sci U S A*. 2008; 105:6912–6917. [PubMed: 18458340]
40. Chen JL, Merl D, Peterson CW, Wu J, Liu PY, Yin H, Muoio DM, Ayer DE, West M, Chi JT. Lactic acidosis triggers starvation response with paradoxical induction of TXNIP through MondoA. *PLoS Genet*. 2010; 6
41. Yu FX, Chai TF, He H, Hagen T, Luo Y. Thioredoxin-interacting protein (Txnip) gene expression: sensing oxidative phosphorylation status and glycolytic rate. *J Biol Chem*. 2010; 285:25822–25830. [PubMed: 20558747]
42. Furugen A, Kobayashi M, Narumi K, Watanabe M, Otake S, Itagaki S, Iseki K. AMP-activated protein kinase regulates the expression of monocarboxylate transporter 4 in skeletal muscle. *Life Sci*. 2011; 88:163–168. [PubMed: 21070787]

**Figure 1.**

Effects of Txnip ablation on AMPK activation and ACC phosphorylation. Tissue homogenates from soleus muscle and hearts were prepared from overnight fasted (A) and non-fasted (B) WT and TKO mice. Equal amounts of protein were resolved by SDS-PAGE. Levels of total AMPK and phospho-AMPK α (pThr-172) were quantified by Western blotting. Results are presented as mean \pm S.D. from 3 mice in each group. C. Phosphorylation levels of the AMPK downstream target ACC (pSer-79) and total ACC were determined by Western blotting. Results are presented as mean \pm S.D. from 3 mice in each group. D. AMPK enzyme activity was determined in homogenates from the heart, soleus and gastrocnemius muscles of fasted WT and TKO mice. Results are presented as mean \pm S.D. from 3 mice in each group. *denotes $p < 0.05$ and ** denotes $p < 0.01$ versus control mice.




Figure 2. Effects of Txnip ablation on Ser-485/491 phosphorylation of AMPK α . Samples were prepared as in Fig. 1. Levels of pSer-485/491 in AMPK α in soleus muscle and hearts were quantified. Results are presented as mean \pm S.D. from 3 mice in each group.




Figure 3.

Effects of Txnip ablation on LKB1 expression and function. (A) Tissue homogenate from soleus muscle of fasted mice was subfractionated into nuclear and cytosolic fractions. Ratios of cytosolic LKB1/total LKB1 and nuclear LKB1/total LKB1 were determined. (B) Levels of phospho-MARK1 (phosphorylation loop). Results are presented as mean \pm S.D. (n = 3).




Figure 4. Induction of AMPK phosphorylation by AICAR. Overnight fasted WT and TKO mice (n=3 per group) were injected (s.c.) with saline or AICAR (0.5mg/g). One hour after the treatment, soleus muscle was harvested. Levels of total AMPK and phospho-AMPK α (Thr-172) were determined by Western blot analysis. A representative blot is shown using duplicate samples from each group. Results are presented as mean \pm S.D. * denotes $p < 0.05$ and NS denotes no significant difference versus WT.




Figure 5. Plasma insulin levels and 2-deoxyglucose uptake. (A) Plasma insulin levels in fasted and non-fasted WT (filled bars) and TKO (hatched bars) mice. Results are presented as mean \pm S.D. (n = 4). (B) 2-deoxyglucose uptake by soleus isolated from fasted WT and TKO mice. Results are presented as mean \pm S.D. (n = 3). ** denotes p<0.01 versus control mice.




Figure 6. Effects of Txnip ablation on GLUT1 and GLUT4 expression. (A) Top panel, heart homogenate from overnight fasted WT mice was subfractionated to obtain enriched plasma membranes, intermembrane vesicles and cytosolic fractions for Western blot analysis. Thirty μg of protein from each fraction was resolved by SDS-PAGE. Bottom panel, GLUT4 expression in plasma membrane of hearts from overnight fasted WT and TKO mice. (B & C) Levels of GLUT1 protein in fasted (B) and non-fasted (C) mice. Results are presented as mean \pm S.D. ($n = 4$). (D) Relative expression of GLUT1 mRNA in the heart, soleus and gastrocnemius muscles of fasted WT and TKO mice. Results are presented as mean \pm S.D. ($n = 5$). * denotes $p < 0.05$ versus control mice and ** denotes $p < 0.01$ versus control mice.




Figure 7. Effects of Txnip ablation on pyruvate dehydrogenase. Levels of phospho-pyruvate dehydrogenase (pSer-293 of PDH-E1 α) in soleus muscles from overnight fasted (A) and non-fasted (B) WT and TKO mice were determined. Results are presented as mean \pm S.D. (n=3). *denotes $p < 0.05$ versus control mice.




Figure 8. Effects of Txnip ablation on glycogen content. Glycogen content in the heart, soleus and gastrocnemius muscles from fasting (A) and non-fasting (B) WT and TKO mice. Results are presented as mean \pm S.D. (n= 3). *denotes $p < 0.05$ and ** denotes $p < 0.01$ versus control mice.

Table 1
Quantitative analysis of cellular adenosine nucleotides in fasted mice by LC/MS

Cellular adenosine nucleotides in overnight fasted WT and TKO mice. Levels of AMP, ADP and ATP in tissue extracts were determined by LC/MS. Normalized results are presented as mean \pm S.D. p values (WT versus TKO) are presented.

Soleus (fasting)	n	AMP ($\mu\text{mol/g}$ tissue)	ADP ($\mu\text{mol/g}$ tissue)	ATP ($\mu\text{mol/g}$ tissue)	AMP:ATP
WT	9	0.318 \pm 0.154	0.632 \pm 0.090	9.297 \pm 1.010	0.034 \pm 0.017
TKO	8	0.093 \pm 0.021	0.587 \pm 0.050	10.635 \pm 1.325	0.009 \pm 0.002
p		0.002	0.221	0.037	0.002
Heart (fasting)	n	AMP ($\mu\text{mol/g}$ tissue)	ADP ($\mu\text{mol/g}$ tissue)	ATP ($\mu\text{mol/g}$ tissue)	AMP:ATP
WT	10	6.529 \pm 1.732	0.654 \pm 0.097	7.066 \pm 0.392	0.927 \pm 0.253
TKO	10	4.440 \pm 1.108	0.631 \pm 0.054	6.379 \pm 0.338	0.699 \pm 0.183
p		0.006	0.526	<0.001	0.034
Gastrocnemius (fasting)	n	AMP ($\mu\text{mol/g}$ tissue)	ADP ($\mu\text{mol/g}$ tissue)	ATP ($\mu\text{mol/g}$ tissue)	AMP:ATP
WT	10	0.206 \pm 0.022	0.471 \pm 0.044	7.158 \pm 0.757	0.029 \pm 0.004
TKO	10	0.201 \pm 0.039	0.564 \pm 0.041	8.719 \pm 0.334	0.023 \pm 0.004
p		0.707	<0.001	<0.001	0.005